Hepatitis Control plan. Where will we make the difference in the next 5 years?

Margaret Walker, CEO, ELPA
VHPB Meeting
London, 5 - 6 June, 2015
ELPA: 35 members from 27 countries
Our work

**Science-oriented**

- Conducting scientific/advisory meetings with pharmaceutical companies
- Distributing and collecting scientific data to and from ELPA members
- Reviewing protocols, working with EMA

**Policy-oriented**

- Conducting policy meetings with ELPA members and other stakeholders in the liver field
- Advocating for patient rights on national and European level
- Engaging with relevant institutional and professional stakeholders
ELPA 10th Anniversary: patients matter!
What are the challenges?

- Treatment registry
- Best practice exchange
- Comparable data
- Affordability
- Availability
- Patient adherence
- Information
- Screening
- Affordability
- Patient adherence
- Screening
- Information
- Comparable data
- Treatment registry
- Best practice exchange
How to address them?

- **National Hepatitis Action Plan**
- **Political will**
- **Guidelines for action**
- **Health economic assessment**
How does ELPA contribute?

National Hepatitis Action Plan

- Political will
- Guidelines for action
- Health economic assessment
- How does ELPA contribute?
Hepatitis B and C:
AN ACTION PLAN FOR SAVING LIVES IN EUROPE
Hepatitis B and C
An action plan for saving lives in Europe
The experts' recommendation summary
Support

Official supporters:

[Logos of EASL, VHPB, World Hepatitis Alliance, Correlation]

Acknowledgement by:

WHO, ECDC, US CDC and HBCPPA
Structure

Overview/ Background

Monitoring and data collection
- Key recommendations

Awareness
- Key recommendations

Prevention
- Key recommendations

Testing and diagnosis
- Key recommendations

Assessment
- Key recommendations

Treatment
- Key recommendations

Conclusion

Bibliography
Conclusion

- A small minority of the infected patients are diagnosed
- Most EU-28 countries have not implemented any preventative activities
- There is a need to develop a consistent, evidence-based approach to address this silent pandemic at the EU level
- The situation in the US provides a learning opportunity to inform action at both European and national level
The Burden of Hepatitis C:
THE CASE OF FRANCE AND ROMANIA
Background

- A project of ELPA (developed by Quantify Research)

- **Selected countries**
  - France (best performance in hepatitis management in Europe)
  - Romania (highest prevalence; poor management)

- **Objectives**
  1. To describe the current burden* of hepatitis C in Europe
  2. To assess the impact of increased treatment

---

*Burden refers to clinical outcomes (e.g. quality of life and mortality) and economic ones*
The model

Mild HCV → Moderate HCV → Cirrhosis → Decompensated cirrhosis → Liver transplantation → Post transplantation

Mild, moderate and cirrhosis (eligible for HCV treatment) → End-stage

Sustained virological response

Hepatocellular carcinoma → Mortality related to liver disease
Case scenarios

- **Scenario A**
  - Patients are treated with current standard of care* and treatment levels are kept constant throughout the model

- **Scenario B**
  - Patients are treated with current standard of care* but treatment levels are increased between 2014 and 2018 after which treatment levels are returned to current levels

- **Scenario C**
  - Patients are treated with drugs of increased efficacy and treatment levels are increased between 2014 and 2018 after which treatment levels are returned to current levels

*Peg-interferon + ribavirin + protease inhibitor in genotype 1 and Peg-interferon + ribavirin in other genotypes in France (average SVR ~57%). Peg-interferon and ribavirin in all genotypes in Romania (average SVR ~33%).
Economic burden of HCV in Romania
Scenario A
Economic burden of HCV in France

Scenario A
The study demonstrates that:

- The burden of hepatitis C is substantial
- The total health care cost is projected to increase unless action is taken
- Treatment investment is essential to:
  - Economic efficiency
  - Decreased morbidity and mortality
Conclusion

- Today’s decisions will have an impact on:
  - Budgets
  - Health outcomes
  - Quality of life
Bibliography


Thank you!